Systematic treatment of advanced non-small cell lung cancer (NSCLC) includes targeted
treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The …

7602 Background: Erlotinib is an orally EGFR TKI approved for the treatment of advanced
non-small-cell lung cancer. Its most frequent and specific toxicity is a rash which generally …

Background The development of a rash has been retrospectively associated with increased
response and improved survival when treated with erlotinib at the standard dose of 150 mg …

BACKGROUND: Dermatological toxicity, usually in the form of acneiform rash, is frequently
observed in non-small-cell lung cancer (NSCLC) patients treated with anti-EGF receptor …

Advances in the knowledge of tumor biology and mechanisms of oncogenesis has granted
the singling out of several molecular targets for non-small cell lung cancer (NSCLC) …

Aim: This analysis investigates incidence and time course of rash in the EURTAC study.
Materials & methods: Patients with EGFR mutation-positive non-small-cell lung cancer were …

The human epidermal growth factor receptor (EGFR) signaling is overexpressed in many
solid malignancies, making it an appealing target for biologic agents. A number of agents …

Purpose Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR)
tyrosine kinase inhibitor. This phase II study of erlotinib in patients with HER1/EGFR …

Background: Severe skin rash as toxicity of erlotinib has been reported in relation to better
response and survival. However, some patients require dose reduction due to skin toxicities …

Abstract Erlotinib (OSI-774; Tarceva™) is an orally available, highly specific epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with …